Vitamin D and airway obstructio

Phase 2

• Conditions: Condition 1: COPD patients. Condition 2: COPD. Condition 3: COPD. Condition 4: COPD. Condition 5: COPD. Condition 6: COPD. Condition 7: COPD. Condition 8: COPD.; Bronchitis, not specified as acute or chronic; Simple and mucopurulent chronic bronchitis; Unspecified chronic bronchitis; Emphysema; Other chronic obstructive pulmonary disease; Asthma; Status asthmaticus; Bronchiectasis

• Registration Number: IRCT201103154724N2
• Lead Sponsor: Vice- chancellor of Researcher Babol university of medical sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Inclusion criteria : All eligible patients with chronic obstructive pulmonary diseases(COPD) will be included to study. Exclusion criteria :Patients with chronic pulmonary infections ;restrictive airway diseases;cor pulmonale;congestive heart failure;pulmonary emboli neoplasia;occupational lung disease and pregnant women will be excluded .

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mean differences in FEV1,FVC,FEV1/FVC,from baseline after 3 and six months. Timepoint: 3 months and 6 months interval. Method of measurement: Pulmonary function test (PFT).

Secondary Outcome Measures

Name	Time	Method
Proportions of patients responded to the treatment (defined as 20% improvement in FEV1 absolute value in ml compared with baseline values) in treatment group compared with placebo group. Timepoint: After 3 months and 6 months of treatment. Method of measurement: PFT.